Clinical Trial Update: Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating camrelizumab combined with an EGFR monoclonal antibody or chemotherapy as perioperative treatment for locally advanced head an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• Chemotherapy (perioperative)
• EGFR monoclonal antibody

Snippet

Sponsor: Yue He, MD | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 3 | Status: NOT_YET_RECRUITING